{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-088549","form_type":"8-K","ticker":null,"cik":"0001888012","company_name":"HilleVax, Inc.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.108629+00:00","generated_at":"2026-05-31T14:30:48.089124+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"HilleVax cuts 41 employees (~40% workforce); expects $3.4M in severance charges","bullets":["Workforce reduced by ~41 employees (40%) to lower operating expenses while preserving core capabilities.","Estimated severance and related charges of $3.4M, majority expected in Q3 2024.","Company will explore continued development of HIL-214 and HIL-216 norovirus vaccine candidates and business development.","Workforce reduction approved by board on July 26, 2024; substantial completion in Q3 2024.","Risks include inability to realize expected cash savings, retain key personnel, or find development path for pipeline candidates."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-088549","json":"https://secwatch.observer/filing/0000950170-24-088549.json","markdown":"https://secwatch.observer/filing/0000950170-24-088549.md","text":"https://secwatch.observer/filing/0000950170-24-088549.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888012/000095017024088549/0000950170-24-088549-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888012/000095017024088549/hlvx-20240726.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:30:48.089124+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"036a70e5b8641df2c226c26e7b584a8447b49add","claim":"HilleVax, Inc. announced a restructuring with charges of workforce reduction of approximately 41 employees affecting entire company (approximately 41 employees, constituting approximately 40% of the Company’s workforce).","evidence_excerpt":"On July 31, 2024, HilleVax, Inc. (the “Company”) announced a workforce reduction of approximately 41 employees, constituting approximately 40% of the Company’s workforce.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888012/000095017024088549/0000950170-24-088549-index.htm","confidence":0.99,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"workforce reduction of approximately 41 employees"},{"label":"Affected area","value":"entire company"},{"label":"Headcount","value":"approximately 41 employees, constituting approximately 40% of the Company’s workforce"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}